Bellevue Group Portfolio holdings
Bellevue Group is a Swiss asset manager that focuses on healthcare investing, small and mid-cap companies and other growth strategies. Martin Bisang and four other founders started it in 1993, and through its subsidiary Bank am Bellevue it first became a major name in brokerage and block trading on the Swiss market. It sold that bank to Luxembourg's KBL Group in 2019, dropping its private client business and becoming a pure asset manager. In 2016 it bought the German asset manager StarCapital to build its presence in Germany, and in 2023 it launched Bellevue Obesity Solutions, a global equity fund.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$5.16M |
| 2 |
Ligand Pharmaceuticals
LGND
|
+$4.22M |
| 3 |
AKRX
Akorn Inc
AKRX
|
+$3.7M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$3.21M |
| 5 |
ENDP
Endo International plc
ENDP
|
+$2.74M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVS Health
CVS
|
+$6.62M |
| 2 |
Cardinal Health
CAH
|
+$6.02M |
| 3 |
MDVN
MEDIVATION, INC.
MDVN
|
+$4.7M |
| 4 |
STJ
St Jude Medical
STJ
|
+$4.68M |
| 5 |
Supernus Pharmaceuticals
SUPN
|
+$3.34M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.88% |
| 2 | Miscellaneous | 1.78% |
| 3 | Financials | 0.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Medtronic
MDT
$129B
| $21.4M | 3.86% |
247,500
-35,000
| -12% | -$3.05M |
2016 Q1
2 quarters
|
|
2
Stryker
SYK
$119B
| $21M | 3.8% |
180,800
+3,800
| +2% | +$443K |
2016 Q1
2 quarters
|
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $20.3M | 3.67% |
194,250
-1,800
| -0.9% | -$195K |
2016 Q1
2 quarters
|
|
4
Illumina
ILMN
$31.7B
| $17.2M | 3.1% |
97,120
+2,981
| +3% | +$477K |
2016 Q1
2 quarters
|
|
5
Biogen
BIIB
$37B
| $17.1M | 3.08% |
54,500
| – | – |
2016 Q1
2 quarters
|
|
6
Abbott
ABT
$186B
| $16.2M | 2.93% |
384,000
+2,500
| +0.7% | +$107K |
2016 Q1
2 quarters
|
|
|
7
Regeneron Pharmaceuticals
REGN
$98.4B
| $15.3M | 2.76% |
38,000
+8,000
| +27% | +$3.21M |
2016 Q1
2 quarters
|
|
8
Amgen
AMGN
$253B
| $13.9M | 2.52% |
83,500
| – | – |
2016 Q1
2 quarters
|
|
9
UnitedHealth
UNH
$363B
| $13.9M | 2.51% |
99,200
| – | – |
2016 Q1
2 quarters
|
|
10
Boston Scientific
BSX
$64.1B
| $13.7M | 2.47% |
575,000
+75,000
| +15% | +$1.79M |
2016 Q1
2 quarters
|
|
11
Gilead Sciences
GILD
$208B
| $12.4M | 2.24% |
156,500
| – | – |
2016 Q1
2 quarters
|
|
|
12
Ligand Pharmaceuticals
LGND
$6.33B
| $10.9M | 1.97% |
171,329
+57,468
| +50% | +$4.22M |
2016 Q1
2 quarters
|
|
13
Zimmer Biomet
ZBH
$19.8B
| $10.4M | 1.88% |
82,400
-6,386
| -7% | -$789K |
2016 Q1
2 quarters
|
|
14
Edwards Lifesciences
EW
$60.8B
| $10.2M | 1.85% |
255,000
+51,000
| +25% | +$1.92M |
2016 Q1
2 quarters
|
|
15
Jazz Pharmaceuticals
JAZZ
$15.4B
| $10.2M | 1.84% |
83,800
+8,500
| +11% | +$1.15M |
2016 Q1
2 quarters
|
|
16
Becton Dickinson
BDX
$58.8B
| $9.9M | 1.79% |
56,375
-4,100
| -7% | -$701K |
2016 Q1
2 quarters
|
|
17
Centene
CNC
$34.8B
| $9.47M | 1.71% |
282,860
+48,100
| +20% | +$1.67M |
2016 Q1
2 quarters
|
|
18
DELISTED
Hologic
HOLX
| $9.4M | 1.7% |
242,100
+3,800
| +2% | +$143K |
2016 Q1
2 quarters
|
|
19
Baxter International
BAX
$13.3B
| $9.04M | 1.63% |
190,000
+24,000
| +14% | +$1.13M |
2016 Q1
2 quarters
|
|
|
20
Viatris
VTRS
$23.7B
| $8.98M | 1.62% |
235,700
+116,000
| +97% | +$5.16M |
2016 Q1
2 quarters
|
|
|
21
Cardinal Health
CAH
$64.3B
| $8.88M | 1.6% |
114,280
-74,500
| -39% | -$6.02M |
2016 Q1
2 quarters
|
|
22
Intuitive Surgical
ISRG
$152B
| $8.7M | 1.57% |
108,000
| – | – |
2016 Q1
2 quarters
|
|
23
Teva Pharmaceutical Industries Limited
TEVA
$50.9B
| $8.61M | 1.56% |
187,190
-42,000
| -18% | -$2.19M |
2016 Q1
2 quarters
|
|
24
Incyte
INCY
$24.8B
| $8.58M | 1.55% |
91,000
| – | – |
2016 Q1
2 quarters
|
|
25
Cigna
CI
$78.1B
| $7.78M | 1.41% |
59,722
+11,722
| +24% | +$1.53M |
2016 Q1
2 quarters
|
|
Similar funds
Bellevue Group's Q3 2016 Portfolio in Review
As of Q3 2016, Bellevue Group held 131 positions worth $553M, up 4.1% from $531M the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Bellevue Group's Q3 2016 filing shows 7 new, 28 increased, 30 reduced and 10 closed positions. Its largest new stake was Insys Therapeutics, Inc.: 115,000 shares worth $1.36M. The largest sale was CVS Health, an estimated $6.62M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Financials.
- Bellevue Group's largest Q3 2016 buy was Insys Therapeutics, Inc.: 115,000 shares worth $1.36M.
- Bellevue Group added most to Viatris in Q3 2016, an estimated $5.16M increase.
- Bellevue Group's biggest Q3 2016 reduction was CVS Health, cutting an estimated $6.62M.
- Bellevue Group fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $4.7M.
- Bellevue Group's ten largest holdings make up 31% of its $553M portfolio in Q3 2016.
- Bellevue Group opened 7 new positions and closed 10 in Q3 2016.
- Bellevue Group's portfolio value rose 4.1% quarter-over-quarter to $553M.
Based on Bellevue Group's 13F filing for Q3 2016, filed 10 Nov 2016.